<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148705</url>
  </required_header>
  <id_info>
    <org_study_id>MW 2010-03-02</org_study_id>
    <nct_id>NCT02148705</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns</brief_title>
  <official_title>A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a three-arms study intending to demonstrate superiority of NexoBrid
      treatment over the Gel Vehicle placebo control treatment and over SOC in thermal burn
      subjects.

      The study objectives are:

        1. To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing
           complete eschar removal as compared with Gel vehicle,

        2. To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing
           earlier complete eschar removal, reduction in patients' surgical burden and its related
           blood loss as compared to SOC,

        3. To assess the safety of NexoBrid compared to SOC, including demonstration that
           treatment with NexoBrid does not cause an unacceptable level of harm on wound closure
           outcome and long term outcomes of cosmesis and function.

      Physicians will define one or more Target Wounds (TWs) per subject according to TWs
      definition. All subjects' deep (DPT and FT) burns that comply with the specified entrance
      criteria are intended to receive study treatment per the randomized study arm.

      The randomization procedure will be initiated only after all Target wounds of a subject have
      been defined. Patients will be assigned to the treatment arm in a 3:3:1 ratio (NexoBrid: SOC
      : Gel Vehicle).

      Patients will be treated in the same way in all study arms (NexoBrid, SOC or Gel vehicle)
      except for the eschar removal stage which will be performed as per the randomization study
      arm.

      Prior to initiation of eschar removal treatment, subjects will be medicated with appropriate
      analgesia and undergo wound cleansing and dressing of all wounds with antibacterial
      solutions . Following wound cleansing and antibacterial treatments, subjects will undergo
      the eschar removal process as per treatment assignment (NexoBrid, SOC or Gel Vehicle,
      following randomization).

      Subsequent to complete eschar removal, all wounds will be assessed and treated in the same
      manner, in accordance with post-eschar removal wound care strategy. Post eschar removal,
      subjects will undergo daily vital signs and pain assessments, until hospital discharge (HD)
      and weekly assessments of wound progress, until wound closure. Following wound closure
      confirmation visit, subjects will be followed up at 1, 3, 6, 12, 18 and 24 months post wound
      closure for long term outcomes evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete eschar removal: Demonstrate superiority over Gel Vehicle</measure>
    <time_frame>post application (post 2 h soaking)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Thermal Burns</condition>
  <arm_group>
    <arm_group_label>NexoBrid Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <arm_group_label>NexoBrid Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gel Vehicle</intervention_name>
    <arm_group_label>Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria- Patient level

          1. Males and females; ≥ 18 and ≤ 70 years of age,

          2. Thermal burns caused by fire/flame, scalds or contact,

          3. Patient total burns area ≥ 3% DPT and / or FT,

          4. Patient total burns area should be ≤ 15% TBSA; SPT, DPT and/or FT in depth,

          5. Informed consent can be obtained within 48 hours of the burn injury,

          6. Patients who are willing and able to sign a written consent form. Inclusion Criteria
             - Wound level

        At least one wound (a continuous burn area which can be treated in one session; may
        include several anatomical areas) in a patient should meet all following criteria:

          1. Wound that is ≥1% TBSA (DPT and/or FT) (not including face, perineal or genital),

          2. Wound's blisters can be removed/unroofed, as judged by the investigator.

        Exclusion Criteria- Patient level

          1. Patients who are unable to follow study procedures and follow up period,

          2. Modified Baux index ≥ 80,

          3. Patients with burned charred fingers, 3rd degree in depth and possibly devoid of
             circulation,

          4. Patients with abraded wound/s that cannot be treated by an enzymatic debrider
             application (NexoBrid) will be excluded from the study,

          5. Patients with electrical, blast or chemical burns,

          6. Patients with DPT and/or FT facial burn wounds from flame, flash, explosion &gt; 0.5%
             TBSA (scald and contact burns are allowed),

          7. Patients with circumferential DPT and/or FT burns defined as Extremities at Risk
             (EAR) ,

          8. The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),

          9. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with
             iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of SSD treatment),

         10. Patients with pre-enrollment escharotomy,

         11. Patients with diagnosed infections as described in Section 11.6.3 of study protocol,

         12. Any signs or history that may indicate smoke inhalation (e.g. flame burn to the upper
             body, flames in enclosed space, smoke and fumes on the patient and in mouth and
             nostrils, deep flame burns &gt;0.5 %TBSA to the face, cough, hoarseness, stridor or
             breathing difficulty including tachypnea possibly related to smoke inhalation, etc.),

         13. Pregnant women (positive pregnancy test) or nursing mothers,

         14. Poorly controlled diabetes mellitus (HbA1c&gt;9%) in patients with known diabetes as
             captured in the medical history,

         15. Patients with BMI greater than 34.0 kg/m2,

         16. ASA greater than 2 (Appendix 13- ASA classification system)

         17. Cardio-pulmonary disease (MI within 6 months prior to injury, pulmonary hypertension,
             COPD or pre-existing oxygen-dependent pulmonary diseases, broncho-pneumonia, steroid
             dependent asthma or uncontrolled asthma),

         18. Pre-existing diseases which interfere with circulation (peripheral vascular disease,
             edema, lymphedema, surgery to regional lymph nodes, obesity, varicose veins),

         19. Any conditions that would preclude safe participation in the study or adding further
             risk to the basic acute burn trauma (such as immuno-compromising diseases, life
             threatening trauma, severe pre-existing coagulation disorder, cardiovascular
             disorder, pulmonary disorder, liver disorder including post alcoholic abuse impaired
             function or neoplastic disease),

         20. Chronic systemic steroid intake,

         21. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or
             papain,

         22. Current (within 12 months prior to screening) suicide attempt,

         23. Mentally incapacitated adults who are incapable of giving legal consent (e.g.
             dementia, psychiatric patients, etc),

         24. Enrollment in any investigational drug trial within 4 weeks prior to screening,

         25. Current (within 12 months prior to screening) alcohol (daily consumption &gt; 3 units
             for males and &gt;2 units for females) or drug abuse ,

         26. Prisoners and incarcerated,

         27. Patients who might depend on the clinical study site or investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Limor Dinur-Klein</last_name>
    <phone>+972-77-9714176</phone>
    <email>limord@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David-Zarbiv</last_name>
    <phone>+972-77-9714103</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Foster, MD</last_name>
      <phone>602-344-5624</phone>
      <email>kevin_foster@dmgaz.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Regional Burn Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bernal, MD</last_name>
      <phone>714-743-1095</phone>
      <email>bernaln@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole Bernal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver, Teaching</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Lindberg, MD</last_name>
      <phone>303-724-2727</phone>
      <email>Gordon.Lindberg@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital Regional Burn Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <phone>813-844-4133</phone>
      <email>dsmith3@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital Joseph M. Research Foundation, Inc.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Mullins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richard M Fairbanks Burn Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv Sood</last_name>
      <email>rsood@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>lucy wibbenmeyer, MD</last_name>
      <email>lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burnett Burn Center at The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <phone>913-588-2000</phone>
      <email>dbhavsar@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital Corporation d/b/a Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Goverman, MD</last_name>
      <phone>617-726-3712</phone>
      <email>JGOVERMAN@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Randolph Hearst Burn Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Gallagher, MD</last_name>
      <phone>212-746-5881</phone>
      <email>jag9027@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emergency Medicine Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook,</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Singer, Dr</last_name>
      <phone>631-444-7857</phone>
      <email>adam.singer@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Jones, MD</last_name>
      <phone>614-293-5710</phone>
      <email>Larry.Jones@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigrid Blome-Eberwein, MD</last_name>
      <phone>610-402-9046</phone>
      <email>Sigri.Blome-Eberwein@lvhn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Kahn, MD</last_name>
      <phone>251-471-7988</phone>
      <email>skahn@health.southalabama.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Firefighters Regional Burn Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William L Hickerson</last_name>
      <phone>901-448-2525</phone>
      <email>bhickerson@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George David Peak Memorial Burn &amp; Wound Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas A Meyer</last_name>
      <phone>414-323-9516</phone>
      <email>Nicholas.Meyer@columbia-stmarys.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Plastic Surgery</name>
      <address>
        <city>Gent</city>
        <zip>B 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stan Monstrey, MD</last_name>
      <phone>0032-(0) 9-332 2220</phone>
      <email>stan.monstrey@UGENT.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika popálenin a rekonstrukční chirurgie, Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Břetislav Lipový</last_name>
      <phone>+420608680701</phone>
      <email>b.lipovy@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hartmann</last_name>
      <phone>030 5681 3501</phone>
      <email>bernd.hartmann@ukb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BG Universitätsklinikum Bergmannsheil GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Lehnhardt</last_name>
      <phone>0234 302 6851</phone>
      <email>marcus.lehnhardt@bergmannsheil.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BG-Kliniken Bergmannstrost</name>
      <address>
        <city>Halle</city>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Siemers</last_name>
      <phone>0345 132 63 33</phone>
      <email>plastische-chirurgie@bergmannstrost.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Süd</name>
      <address>
        <city>Nürnberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Reichert</last_name>
      <phone>0911 398 2367</phone>
      <email>reichert@klinikum-nuernberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yehuda Ullmann</last_name>
      <phone>04-7773249</phone>
      <email>y_ullmann@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta de Chirurgie Plastica, Reparatorie si Arsuri</name>
      <address>
        <city>Bucharest</city>
        <zip>010713</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tudor Andrei Stancioiu</last_name>
      <phone>004 0723513914</phone>
      <email>andrei.t.stancioiu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta &quot;Prof. Dr. Agrippa Ionescu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011356</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christan Radu Jecan</last_name>
      <phone>40745073815</phone>
      <email>silviubadoiu@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta &quot;Sf. Ioan&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>042122</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Giuglea</last_name>
      <phone>+4 0723216718</phone>
      <email>giugleacarmen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta &quot;Bagdasar-Arseni&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>41915</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silviu Adrian Marinescu</last_name>
      <phone>40752182696</phone>
      <email>Silviumarinescu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 27, 2016</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fire/flame</keyword>
  <keyword>scalds</keyword>
  <keyword>contact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
